The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Obecabtagene autoleucel in adult patients with R/R B-ALL: Results from FELIX trial
|
Obe-cel is an autologous, anti-CD19 CAR T-cell therapy approved for the treatment of adults with R/R B-ALL. This approval was based on results from the FELIX trial (NCT04404660). Results from this study were published in The New England Journal of Medicine by Roddie et al.1 The primary endpoint was overall remission in the II A cohort.1 |
| Key learnings |
| After a median follow-up of 20.3 months, the overall remission, CR, and CR/CRi rates were 77%, 55%, and 21%, respectively. |
| Median EFS was 11.9 months; estimated 6-month and 12-month EFS were 65.4% and 49.5%. The median OS was 15.6 months; estimated 6-month and 12-month OS were 80.3% and 61.1%. |
| CRS and ICANS were reported in 69% and 23% of patients; Grade ≥3 CRS and ICANS were 2.4% and 7.1%. |
| Results from the FELIX trial support the use of obe-cel in adult patients with R/R B-ALL. |
Abbreviations: B-ALL, B-cell acute lymphoblastic leukemia; CAR, chimeric antigen receptor; CR, complete remission; CRi, CR with incomplete hematologic recovery; CRS, cytokine release syndrome; EFS, event-free survival; ICANS, immune effector cell-associated neurotoxicity; obe-cel, obecabtagene autoleucel; OS, overall survival; R/R, relapsed/refractory.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
